ClinicalTrials.gg
TerminatedNCT01358214Updated Aug 23, 2012

Quality of Life After Tension Free Transvaginal Sling / Tape Operation With a Titanized Surgical Tape (TiLOOP® Tape)

An observational study in Urinary Incontinence, Stress, sponsored by pfm medical gmbh. Terminated at 1 site in Germany. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-08-23.

Sponsored by pfm medical gmbh · Observational

How we know

Why this study was terminated
major recruitment failure

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
21
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Urinary Incontinence, Stress with a site in Germany — 1 open to participants now, 3 under way, none of them phase 3. Urinary Incontinence, Stress · Germany.

Enrollment
12th of 12
21 · median 199
Started
2011
with 2 others
Observational
12 of 26
1 open now
Registered
6th of 26
by date

Among the 26 studies in Urinary Incontinence, Stress with a site in Germany, this one is the 12th largest by enrollment of the 12 observational ones that give a count, is one of 3 that started in 2011, is one of 12 observational ones, and was the 6th registered.

Urinary Incontinence, Stress

655 studies on the registry are indexed under Urinary Incontinence, Stress; 123 are open to participants now.

Browse Urinary Incontinence, Stress studies →

Open to participants now

1 of the 26 studies in Urinary Incontinence, Stress with a site in Germany is open now. Recruiting first, the newest first:

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 76 Urinary Incontinence, Stress studies recruiting now, 43 (57%) set no upper age limit and 18 (24%) stop at 75 or younger; 2 take children under 18; 16 take healthy volunteers.

This study: female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Urinary Incontinence, Stress with a site in Germany, or all of them as a file.
02

Study summary

Validation of a new Quality of Life (QoL) questionnaire in a population of patient gaining a TiLOOP® TAPE surgical mesh for stabilization of the urethra.

Read the detailed description

The prevalence of urinary incontinence in the adult female population has been estimated between 10% and 40%. Several treatment alternatives have been suggested until now. Nevertheless, the ideal treatment has not been identified yet. On the one hand this is related to the low amount of valid scientific information regarding different treatment methods. On the other hand the impact of patients' quality of life, which plays a major role, has not been fully considered. To date, there is no established Questionnaire on Quality of Life that provides physicians an assistance to obtain information on the subjective effects caused by stress urinary incontinence.

In the present study the patients' Quality of Life will be assessed by use of two questionnaires, that is a new one and an already validated questionnaire. The study population consists of patients who already received an implantation of a sub-urethral surgical mesh (TiLOOP® Tape), of symptomatic patients before an operation, and of a group of non-symptomatic women. Subjects will be asked in a single visit only to fill in both questionnaires.

Furthermore the safety and effectiveness of the TiLOOP® Tape mesh will be evaluated in the study arm of treated patients.

Study has been terminated after major recruitment failure (only 21 instead of 240 patients has been included).

03

Conditions studied

  • Urinary Incontinence, Stress

Keywords

  • Sub-urethral Sling
  • Treatment Outcome
  • Quality of Life
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The indicated or treated population of women showing stress urinary incontinence that should / has been treated with a surgical mesh.

The sample of patients treated with TiLOOP® Tape at the single center between 2007 and 2009 represents the patient population for which the medical device is intended. The clinic continues to examine women with incontinence symptoms requiring a mesh implant. This group of patients is assumed to be similar to the study arm of treated patients.

The Non-symptomatic Population consists of women comparable in age but without urinary incontinence

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Depending on study arm:
  • Women with a TiLOOP® Tape implant, Implanted between 2007 and 2009 at the study center - OR -
  • Woman with a planned Tape implantation at the study center - OR -
  • Woman with no disease related to incontinence
  • Subject is able to understand the nature, relevance and significance of the clinical trial
  • Subject has given

Exclusion criteria

Exclusion Criteria:

  • Subject revoked consent
  • Lack of subject's compliance regarding data collection or examination in the scope of the trial (Non-Compliance)
  • Subject institutionalized by court or official order (MPG §20.3)
  • Subject participates in another clinical investigation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
21 participants (actual)

Groups and cohorts

  • Patients treated with a surgical mesh

    This arm of study patients is defined by patients treated with a TiLOOP® Tape mesh between 2007 and 2009 at the Franziskus Krankenhaus, Berlin. The sample of the treated population represents the patient population for which the medical device is intended. To minimize selection bias without compromising patients' rights and welfare, all treated patients will be invited. These patients will be asked to participate in the validation of the questionnaire on quality of life. In addition to this safety and effectiveness of the surgical mesh implantation will be collected

    Behavioral: Questionnaire on Quality of Life.

  • Intended to be treated with a mesh

    This arm of the study populations is defined by patients in whom a clinical anamnesis independent of the requirements of this study suggests that a sub-urethral sling operation is indicated. These patients will be asked to participate in the validation of the questionnaire on quality of life.

    Behavioral: Questionnaire on Quality of Life.

  • Non-symptomatic Population

    This arm of the study population is defined by women that show no symptoms of incontinence. They will be asked to participate in the validation of the questionnaire on quality of life.

    Behavioral: Questionnaire on Quality of Life.

Interventions

  • BehavioralQuestionnaire on Quality of Life.

    The impact of a disease on patient's Quality of Life has meanwhile gained more influences on the choice of treatment alternatives. The benefit of a method is currently not only defined by the objective outcome but also influenced by the Quality of Life. Two questionnaires with 20 respectively 40 Questions should be filled in by the patients.

    Also known as: QoL

06

What researchers measure

Primary outcomes

  1. Validation of a new questionnaire on quality of life

    It is expected that the newly developed questionnaire on quality of life (QoL) is equal or better in description of the impact on QoL regarding the differentiation of the study populations, as compared to the standard questionnaire.

    Time frame: before treatment (baseline) or 6 to 24 months after treatment, respectively

Secondary outcomes

  1. Safety of surgical mesh implantation for treatment of urinary incontinence

    In the study arm of treated patients the study outcome will describe all safety relevant events occurred within the period from implantation until scheduled study examination. The time between scheduled examination and implantation varies as the implantation it not part of this study. The findings will therefore be stratified by 6 months, 12 months and 24 months after implantation.

    Time frame: 6-24 months after treatment

  2. Effectiveness of surgical mesh implantation for treatment of urinary incontinence

    In the study arm of treated patients, the study outcome will describe the efficacy of the TiLOOP® Tape implantation based on successful implantation and complications observed during the period from implantation until discharge from the hospital. The time between scheduled examination and implantation varies as the implantation it not part of this study. The findings will therefore be stratified by 6 months, 12 months and 24 months after implantation.

    Time frame: 6-24 months after treatment

07

Study locations

1 site
  • Franziskus-Krankenhaus Berlin Akademisches Lehrkrankenhaus der Charité - Universtätsmedizin Berlin
    Berlin, 10787, Germany
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2011
First posted
May 23, 2011
Start
May 2011
Primary completionActual
Feb 2012
CompletionActual
Feb 2012
Last update
Aug 23, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01358214
Lead sponsor
pfm medical gmbh
Collaborators
Aix Scientifics
Responsible party
Sponsor
First posted
May 23, 2011
Start date
May 2011
Primary completion
Feb 2012
Completion
Feb 2012
Last update
Aug 23, 2012

Study contacts

Manfred Beer, Prof. MD
principal investigator · Franziskus-Krankenhaus Berlin Akademisches Lehrkrankenhaus der Charité - Universtätsmedizin Berlin

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion